Sameem Abedin, MD
Hematology & Oncology · Milwaukee, WINPI 1063641157
Payments from drug & device makers
Across 337 payments — averaging $9751.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$957K
- Incyte Corporation$736K
- Pfizer$488K
- National Marrow Donor Program$410K
- Janssen Research & Development, LLC$221K
- Astellas Pharma Global Development$199K
- plus $274K from 15 others
Across 3 payments — averaging $57.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$104
- Astellas Pharma Global Development$69
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 63 | $957,228 |
| Incyte Corporation | 46 | $736,076 |
| Pfizer | 11 | $488,344 |
| National Marrow Donor Program | 18 | $410,085 |
| Janssen Research & Development, LLC | 34 | $221,446 |
| Astellas Pharma Global Development | 51 | $199,105 |
| GSK | 19 | $124,209 |
| AbbVie | 29 | $70,129 |
| Autolus Inc | 11 | $27,200 |
| Servier Pharmaceuticals LLC | 18 | $12,573 |
| Sanofi | 6 | $10,470 |
| Helsinn Healthcare SA | 8 | $9,579 |
| Amgen | 1 | $5,841 |
| Jazz Pharmaceuticals Inc. | 6 | $4,313 |
| Agios Pharmaceuticals, Inc. | 9 | $4,103 |
| Stemline Therapeutics Inc. | 1 | $2,750 |
| Daiichi Sankyo Inc. | 2 | $2,060 |
| AstraZeneca | 1 | $525 |
| Medexus Pharma, Inc. | 1 | $169 |
| Sanofi-aventis U.S. LLC | 1 | $43 |
| Avion Pharmaceuticals | 1 | $15 |
How this compares
$3,286,262 in reported general payments places this provider in the 95th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Milwaukee
- Binod DhakalMilwaukee$13.9M
- Ehab AtallahMilwaukee$13.3M
- Guru Subramanian Guru MurthyMilwaukee$7.2M
- Parameswaran HariMilwaukee$5.8M
- Meera MohanMilwaukee$5.6M
- Deepak KilariMilwaukee$4.7M
- Kathryn BylowMilwaukee$4.5M
- Sayed Mehdi HamadaniMilwaukee$3.7M
- Anita DsouzaMilwaukee$3.7M
- Wael SaberMilwaukee$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.